Meta‐analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer. BJS 2018; 105: 784-796.
Published: 31st October 2017
Authors: U. Nitsche, C. Stöß, L. Stecher, D. Wilhelm, H. Friess, G. O. Ceyhan et al.
It is not clear whether resection of the primary tumour (when there are metastases) alters survival and/or whether resection is associated with increased morbidity. This systematic review and meta‐analysis assessed the prognostic value of primary tumour resection in patients presenting with metastatic colorectal cancer.
A systematic review of MEDLINE/PubMed was performed on 12 March 2016, with no language or date restrictions, for studies comparing primary tumour resection
Of 37 412 initially screened articles, 56 retrospective studies with 148 151 patients met the inclusion criteria. Primary tumour resection led to an improvement in overall survival of 7·76 (95 per cent c.i. 5·96 to 9·56) months (risk ratio (RR) for overall survival 0·50, 95 per cent c.i. 0·47 to 0·53), but did not significantly reduce the risk of obstruction (RR 0·50, 95 per cent c.i. 0·16 to 1·53) or bleeding (RR 1·19, 0·48 to 2·97). Neither was the morbidity risk altered (RR 1·14, 0·77 to 1·68). Heterogeneity between the studies was high, with a calculated
Primary tumour resection may provide a modest survival advantage in patients presenting with metastatic colorectal cancer.Full text
You may also be interested in
Authors: L. Koskenvuo, N. Malila, J. Pitkäniemi, J. Miettinen, S. Heikkinen, V. Sallinen et al.
Notes: Only of benefit in men.
Authors: I. van 't Sant, W. J. van Eden, M. P. Engbersen, N. F. M. Kok, K. Woensdregt, D. M. J. Lambregts et al.
Notes: Promising staging tool
Authors: C. T. Aquina, A. Z. Becerra, Z. Xu, C. F. Justiniano, K. Noyes, J. R. T. Monson et al.
Notes: Non‐operative management better
Cost‐effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.
Authors: G. M. W. Bjørnelv, S. Dueland, P.‐D. Line, P. Joranger, Å. A. Fretland, B. Edwin et al.
Notes: Not for every country
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. BJS 2018; 105: 1553-1572.
Authors: R. Clifford, N. Govindarajah, J. L. Parsons, S. Gollins, N. P. West, D. Vimalachandran et al.
Notes: Promising agents coming
Authors: R. Ahl, P. Matthiessen, X. Fang, Y. Cao, G. Sjolin, R. Lindgren et al.
Notes: Reduces mortality
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Notes: Sigmoid resection associated with bowel dysfunction
Authors: J. Segelman, C. Buchli, A. Svanström Röjvall, P. Matthiessen, S. Arver, M. Bottai et al.
Notes: Ovarian androgens reduced
Randomized clinical trial
Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. BJS 2018; 105: 1417-1425.
Authors: E. Akgun, C. Caliskan, O. Bozbiyik, T. Yoldas, M. Sezak, S. Ozkok et al.
Notes: Worth waiting
CCR‐CARESS score for predicting operative mortality in patients with colorectal cancer. BJS 2018; 105: 1853-1861.
Authors: M. Baré, L. Mora, N. Torà, M. J. Gil, I. Barrio, P. Collera et al.
Notes: Elderly co‐morbid patients at high risk
Preoperative oral care and effect on postoperative complications after major cancer surgery. BJS 2018; 105: 1688-1696.
Authors: M. Ishimaru, H. Matsui, S. Ono, Y. Hagiwara, K. Morita, H. Yasunaga et al.
Notes: Preoperative dental care reduces postoperative pneumonia
Prognostic implications of MRI‐detected lateral nodal disease and extramural vascular invasion in rectal cancer. BJS 2018; 105: 1844-1852.
Authors: D. P. Schaap, A. Ogura, J. Nederend, M. Maas, J. S. Cnossen, G. J. Creemers et al.
Notes: Defines recurrence risk